Humacyte Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | -2.3% | -0.7% | +1.9% | -117.8% | – | +1.5% | +0.3% | -28.1% | +33.5% | +24.8% | – | |
| – | -20.7% | +3.4% | -1.2% | +8.0% | +9.1% | +46.8% | -6.1% | +5.4% | +0.4% | +28.3% | -17.7% | – | |
| – | -55.6% | -248.8% | – | -15.9% | -182.4% | – | – | – | – | – | – | – | |
| – | -69.6% | +160.7% | -52.9% | +407.6% | -93.3% | +261.9% | +149.1% | -91.4% | -20.4% | +348.7% | -40.6% | – | |
| – | -69.6% | +160.7% | -52.9% | +407.6% | -93.3% | +261.9% | +149.1% | -91.4% | -20.4% | +348.7% | -40.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +0.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | +2.1% | +2.1% | +5.8% | +2.2% | – | -100.0% | – | – | |
| – | -56.2% | – | -100.7% | – | +5,907.8% | -8.4% | -95.4% | -2,158.7% | – | -59.2% | +129.5% | – | |
| – | – | – | -162.8% | – | – | -26.5% | -239.4% | – | – | -106.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.